NUBEQA® (darolutamide) Impact on Local Symptoms Evaluated in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Retrieved on:
Tuesday, September 14, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Prostate, Man, Quality of life, MFS, ADT, CPI, Tissue, Patient, Research, Hematuria, European Organization for Quality, Phase, Medical director, Severe cutaneous adverse reactions, Physician, Pneumonia, Urinary retention, The Rheumatoid Arthritis Quality of Life Questionnaire, FACS, Treatment, Pharmaceutical industry, Medical imaging, NUBEQA® (darolutamide)2, Prostate Cancer, Oncology at Bayer, Bayer, NUBEQA® (DAROLUTAMIDE)2, PROSTATE CANCER, ONCOLOGY AT BAYER, BAYER
Local symptoms from the prostate and surrounding tissues can be very detrimental to patients QoL.
Key Points:
- Local symptoms from the prostate and surrounding tissues can be very detrimental to patients QoL.
- NUBEQA (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
- Effect of Other Drugs on NUBEQA Combined P-gp and strong or moderate CYP3A4 inducers decrease NUBEQA exposure, which may decrease NUBEQA activity.
- Impact of darolutamide on local symptoms in patients with nonmetastatic castration-resistant prostate cancer [abstract].